Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,261,681 papers from all fields of science
Search
Sign In
Create Free Account
LJC 10627
Known as:
LJC-10627
, LJC10,627
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
biapenem
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
In vitro antibacterial activity and beta-lactamase stability of the new carbapenem LJC10,627
M. Yoshida
,
S. Mitsuhashi
European Journal of Clinical Microbiology and…
2005
Corpus ID: 5761923
In in vitro susceptibility tests the new carbapenem LJC10,627 showed potent antibacterial activity against gram-positive and gram…
Expand
1994
1994
In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
H. Chen
,
D. Livermore
The Journal of antimicrobial chemotherapy
1994
Corpus ID: 26148231
The activity of biapenem (L-627, LJC-10627), a new carbapenem, was investigated against Pseudomonas aeruginosa strains, mutants…
Expand
1991
1991
In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I
P. Petersen
,
N. Jacobus
,
W. Weiss
,
R. Testa
Antimicrobial Agents and Chemotherapy
1991
Corpus ID: 8587673
The activity of LJC10,627 was compared with the activities of imipenem and other antibiotics. LJC10,627 was more active against…
Expand
Highly Cited
1990
Highly Cited
1990
In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I
K. Ubukata
,
M. Hikida
,
+5 authors
S. Mitsuhashi
Antimicrobial Agents and Chemotherapy
1990
Corpus ID: 20071112
The in vitro activity of LJC10,627, a new carbapenem, was compared with those of imipenem and ceftazidime. LJC10,627 had broad…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE